Success Metrics

Clinical Success Rate
83.3%

Based on 15 completed trials

Completion Rate
83%(15/18)
Active Trials
3(9%)
Results Posted
13%(2 trials)
Terminated
3(9%)

Phase Distribution

Ph not_applicable
4
13%
Ph phase_1
3
9%
Ph phase_3
5
16%
Ph early_phase_1
2
6%
Ph phase_4
10
31%
Ph phase_2
5
16%

Phase Distribution

5

Early Stage

5

Mid Stage

15

Late Stage

Phase Distribution29 total trials
Early Phase 1First-in-human
2(6.9%)
Phase 1Safety & dosage
3(10.3%)
Phase 2Efficacy & side effects
5(17.2%)
Phase 3Large-scale testing
5(17.2%)
Phase 4Post-market surveillance
10(34.5%)
N/ANon-phased studies
4(13.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

15 of 19 finished

Non-Completion Rate

21.1%

4 ended early

Currently Active

3

trials recruiting

Total Trials

32

all time

Status Distribution
Active(6)
Completed(15)
Terminated(4)
Other(7)

Detailed Status

Completed15
unknown7
Terminated3
Not yet recruiting2
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
3
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (6.9%)
Phase 13 (10.3%)
Phase 25 (17.2%)
Phase 35 (17.2%)
Phase 410 (34.5%)
N/A4 (13.8%)

Trials by Status

withdrawn13%
unknown722%
terminated39%
active_not_recruiting13%
not_yet_recruiting26%
enrolling_by_invitation13%
recruiting26%
completed1547%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06052787Phase 3

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Completed
NCT05821075Phase 1

Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Recruiting
NCT03480698

Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Completed
NCT05755997Phase 2

CERebrolysin In CADASIL

Active Not Recruiting
NCT06677502Not Applicable

Cerebrolysin in Critically Ill Patients With Delirium

Enrolling By Invitation
NCT06208540Phase 4

Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

Completed
NCT06489925Early Phase 1

Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion

Not Yet Recruiting
NCT06339411Early Phase 1

Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights

Not Yet Recruiting
NCT06273020Phase 4

Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Recruiting
NCT00947531Phase 4

A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Completed
NCT05864677Not Applicable

Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery

Unknown
NCT00868283Phase 4

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

Completed
NCT06078215Phase 4

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Unknown
NCT06070753Not Applicable

A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)

Unknown
NCT04427241Phase 4

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Unknown
NCT05807503

Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury

Completed
NCT04830943Phase 3

Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia

Completed
NCT04904341Phase 3

Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Unknown
NCT04124367Phase 2

IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE

Terminated
NCT02541227

Cerebrolysin REGistry Study in Stroke

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
32